Selecting patient-reported outcome measures for a patient-facing technology.

IF 2.5 Q2 HEALTH CARE SCIENCES & SERVICES
JAMIA Open Pub Date : 2023-12-13 eCollection Date: 2023-12-01 DOI:10.1093/jamiaopen/ooad104
Priyank Raj, Youmin Cho, Yun Jiang, Yang Gong
{"title":"Selecting patient-reported outcome measures for a patient-facing technology.","authors":"Priyank Raj, Youmin Cho, Yun Jiang, Yang Gong","doi":"10.1093/jamiaopen/ooad104","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This article provides insight into our process and considerations for selecting patient-reported outcome measures (PROMs) designed for self-reporting symptoms and quality-of-life among breast cancer (BCA) patients undergoing oral anticancer agent treatment via a patient-facing technology (PFT) platform.</p><p><strong>Methods: </strong>Following established guidelines, we conducted a thorough assessment of a specific set of PROMs, comparing their content to identify the most suitable options for studying BCA patients.</p><p><strong>Results: </strong>We recommend utilizing the combination of EORTC QLQ-C30 + EORTC QLQ-BR45 as the preferred instrument, especially when developing a dedicated \"breast cancer-only\" application.</p><p><strong>Discussion: </strong>When developing and maintaining a dashboard for a PFT platform that includes multiple cancer types, it is important to consider the feasibility of interface design and workload. To achieve this, we recommend using PRO-CTCAE+PROMIS 10 GH for the PFT. Moreover, it is important to consider adding ad hoc items to complement the chosen PROM(s).</p><p><strong>Conclusion: </strong>This article describes our efforts to identify PROMs for self-reported data while considering patient and developer burdens, providing guidance to PFT developers facing similar challenges in PROM selection.</p>","PeriodicalId":36278,"journal":{"name":"JAMIA Open","volume":"6 4","pages":"ooad104"},"PeriodicalIF":2.5000,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10719077/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMIA Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jamiaopen/ooad104","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This article provides insight into our process and considerations for selecting patient-reported outcome measures (PROMs) designed for self-reporting symptoms and quality-of-life among breast cancer (BCA) patients undergoing oral anticancer agent treatment via a patient-facing technology (PFT) platform.

Methods: Following established guidelines, we conducted a thorough assessment of a specific set of PROMs, comparing their content to identify the most suitable options for studying BCA patients.

Results: We recommend utilizing the combination of EORTC QLQ-C30 + EORTC QLQ-BR45 as the preferred instrument, especially when developing a dedicated "breast cancer-only" application.

Discussion: When developing and maintaining a dashboard for a PFT platform that includes multiple cancer types, it is important to consider the feasibility of interface design and workload. To achieve this, we recommend using PRO-CTCAE+PROMIS 10 GH for the PFT. Moreover, it is important to consider adding ad hoc items to complement the chosen PROM(s).

Conclusion: This article describes our efforts to identify PROMs for self-reported data while considering patient and developer burdens, providing guidance to PFT developers facing similar challenges in PROM selection.

为面向患者的技术选择患者报告的结果指标。
目的:本文深入介绍了我们选择患者报告结果测量指标(PROMs)的过程和考虑因素,这些指标旨在通过面向患者的技术(PFT)平台自我报告接受口服抗癌药治疗的乳腺癌(BCA)患者的症状和生活质量:按照既定指南,我们对一组特定的 PROMs 进行了全面评估,比较了它们的内容,以确定最适合研究 BCA 患者的选项:结果:我们建议将 EORTC QLQ-C30 + EORTC QLQ-BR45 组合作为首选工具,尤其是在开发 "乳腺癌专用 "应用程序时:在开发和维护包含多种癌症类型的 PFT 平台仪表板时,必须考虑界面设计和工作量的可行性。为此,我们建议在 PFT 中使用 PRO-CTCAE+PROMIS 10 GH。此外,重要的是要考虑增加临时项目,以补充所选的 PROM:本文介绍了我们在考虑患者和开发人员负担的同时为自我报告数据确定 PROM 所做的努力,为在 PROM 选择方面面临类似挑战的 PFT 开发人员提供了指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JAMIA Open
JAMIA Open Medicine-Health Informatics
CiteScore
4.10
自引率
4.80%
发文量
102
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信